Estimating typical, best-case and worst-case life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer: A systematic review of contemporary randomized trials

Lung Cancer

Volumn 77, Issue 3, 2012, Pages 537-544

  Kiely, B E ^a   Alam, M ^a,d   Blinman, P ^a,b,d   Tattersall, M H N ^b,c   Stockler, M R ^a,b,c,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b SYDNEY CANCER CENTRE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Australasian Lung Cancer Trials Group   (Australia)

Author keywords

Chemotherapy; Non small cell lung cancer; Prognosis; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; IFOSFAMIDE; MITOMYCIN C; NAVELBINE; PACLITAXEL;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; FOLLOW UP; HUMAN; LIFE EXPECTANCY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; KAPLAN-MEIER ESTIMATE; LIFE EXPECTANCY; LUNG NEOPLASMS; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84865178969     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.04.017     Document Type: Article

References (17)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Visbal A.L., Leighl N.B., Feld R., Shepherd F.A. Adjuvant chemotherapy for early-stage non-small cell lung cancer. Chest 2005, 128:2933-2943.
3. Group NM-AC Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008, 26:4617-4625.
4. Brown J., Thorpe H., Napp V., Fairlamb D.J., Gower N.H., Milroy R., et al. Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer. J Clin Oncol 2005, 23:7417-7427.
5. Innes S., Payne S. Advanced cancer patients' prognostic information preferences: a review. Palliat Med 2009, 23:29-39.
6. Butow P.N., Dowsett S., Hagerty R., Tattersall M.H. Communicating prognosis to patients with metastatic disease: what do they really want to know?. Support Care Cancer 2002, 10:161-168.
7. Hagerty R.G., Butow P.N., Ellis P.M., Dimitry S., Tattersall M.H. Communicating prognosis in cancer care: a systematic review of the literature. Ann Oncol 2005, 16:1005-1053.
8. Hagerty R.G., Butow P.N., Ellis P.M., Lobb E.A., Pendlebury S.C., Leighl N., et al. Communicating with realism and hope: incurable cancer patients' views on the disclosure of prognosis. J Clin Oncol 2005, 23:1278-1288.
9. Davey H.M., Butow P.N., Armstrong B.K. Cancer patients' preferences for written prognostic information provided outside the clinical context. Br J Cancer 2003, 89:1450-1456.
10. Lobb E.A., Butow P.N., Kenny D.T., Tattersall M.H. Communicating prognosis in early breast cancer: do women understand the language used?. Med J Aust 1999, 171:290-294.
11. Stockler M.R., Tattersall M.H., Boyer M.J., Clarke S.J., Beale P.J., Simes R.J. Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer. Br J Cancer 2006, 94:208-212.
12. Kiely B.E., Tattersall M.H., Stockler M.R. Certain death in uncertain time: informing hope by quantifying a best case scenario. J Clin Oncol 2010, 28:2802-2804.
13. Kiely B.E., Soon Y.Y., Tattersall M.H., Stockler M.R. How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. J Clin Oncol 2011, 29:456-463.
14. Hotta K., Fujiwara Y., Matsuo K., Suzuki T., Kiura K., Tabata M., et al. Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy. Cancer 2007, 109:939-948.
15. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
16. Fukuoka M., Wu Y.L., Thongprasert S., Sunpaweravong P., Leong S.S., Sriuranpong V., et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011, 29:2866-2874.
17. Sederholm C., Hillerdal G., Lamberg K., Kolbeck K., Dufmats M., Westberg R., et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol 2005, 23:8380-8388.